Prostate Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Prostate Cancer, including details on symptoms, genetics, screening, treatment, information.

Volume 2 (2005), Issue 1 (January)

1. Peripheral T cell tolerance occurs early during spontaneous prostate cancer development and can be rescued by dendritic cell immunization.
   Eur J Immunol, 35(1): 66-75. [Abstract] [Full-text]
2. Osteoblasts in prostate cancer metastasis to bone.
   Nat Rev Cancer, 5(1): 21-8. [Abstract] [Full-text]
3. The effect of an endorectal balloon and off-line correction on the interfraction systematic and random prostate position variations: a comparative study.
   Int J Radiat Oncol Biol Phys, 61(1): 278-88. [Abstract] [Full-text]
4. Quantification of shape variation of prostate and seminal vesicles during external beam radiotherapy.
   Int J Radiat Oncol Biol Phys, 61(1): 228-38. [Abstract] [Full-text]
5. Impact of tumor repopulation on radiotherapy planning.
   Int J Radiat Oncol Biol Phys, 61(1): 220-7. [Abstract] [Full-text]
6. ATM sequence variants are predictive of adverse radiotherapy response among patients treated for prostate cancer.
   Int J Radiat Oncol Biol Phys, 61(1): 196-202. [Abstract] [Full-text]
7. Factors associated with the frequency of self-intermittent catheterization after prostate brachytherapy.
   Int J Radiat Oncol Biol Phys, 61(1): 60-3. [Abstract] [Full-text]
8. Dosimetry and cancer control after low-dose-rate prostate brachytherapy.
   Int J Radiat Oncol Biol Phys, 61(1): 52-9. [Abstract] [Full-text]
9. Randomized trial of high- and low-source strength (125)I prostate seed implants.
   Int J Radiat Oncol Biol Phys, 61(1): 44-51. [Abstract] [Full-text]
10. Impact of supplemental external beam radiotherapy and/or androgen deprivation therapy on biochemical outcome after permanent prostate brachytherapy.
    Int J Radiat Oncol Biol Phys, 61(1): 32-43. [Abstract] [Full-text]
11. Vessel-sparing prostate radiotherapy: dose limitation to critical erectile vascular structures (internal pudendal artery and corpus cavernosum) defined by MRI.
    Int J Radiat Oncol Biol Phys, 61(1): 20-31. [Abstract] [Full-text]
12. Assessing the impact of an alternative biochemical failure definition on radiation dose response for high-risk prostate cancer treated with external beam radiotherapy.
    Int J Radiat Oncol Biol Phys, 61(1): 14-9. [Abstract] [Full-text]
13. Inhibition of prostate cancer cell growth by an avocado extract: role of lipid-soluble bioactive substances.
    J Nutr Biochem, 16(1): 23-30. [Abstract] [Full-text]
14. Direct evidence that PTHrP expression promotes prostate cancer progression in bone.
    Biochem Biophys Res Commun, 327(2): 468-72. [Abstract] [Full-text]
15. Corpora amylacea in adenocarcinoma of the prostate: incidence and histology within needle core biopsies.
    Mod Pathol, 18(1): 36-9. [Abstract] [Full-text]
16. Cytotoxicity of epigallocatechin-3-gallate to LNCaP cells in the presence of Cu2+.
    J Zhejiang Univ Sci B, 6(2): 125-31. [Abstract] [Full-text]
17. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors.
    J Natl Cancer Inst, 97(1): 59-69. [Abstract] [Full-text]
18. Diabetes and risk of prostate cancer in a prospective cohort of US men.
    Am J Epidemiol, 161(2): 147-52. [Abstract] [Full-text]
19. Potent bombesin-like peptides for GRP-receptor targeting of tumors with 99mTc: a preclinical study.
    J Med Chem, 48(1): 100-10. [Abstract] [Full-text]
20. Tissue-print and print-phoresis as platform technologies for the molecular analysis of human surgical specimens: mapping tumor invasion of the prostate capsule.
    Nat Med, 11(1): 95-101. [Abstract] [Full-text]
21. Sexual function after permanent 125I-brachytherapy for prostate cancer.
    Int J Impot Res, 17(1): 96-101. [Abstract] [Full-text]
22. Loss of HOXC6 expression induces apoptosis in prostate cancer cells.
    Oncogene, 24(1): 188-98. [Abstract] [Full-text]
23. Prevention of hormone-related cancers: prostate cancer.
    J Clin Oncol, 23(2): 368-77. [Abstract] [Full-text]
24. Manganese superoxide dismutase overexpression inhibits the growth of androgen-independent prostate cancer cells.
    Oncogene, 24(1): 77-89. [Abstract] [Full-text]
25. Microarray analysis of bicalutamide action on telomerase activity, p53 pathway and viability of prostate carcinoma cell lines.
    J Pharm Pharmacol, 57(1): 83-92. [Abstract] [Full-text]
26. Differential endostatin binding to bladder, prostate and kidney tumour vessels.
    BJU Int, 95(1): 174-9. [Abstract] [Full-text]
27. Genetic polymorphism of glutathione S-transferase genes (GSTM1, GSTT1 and GSTP1) and susceptibility to prostate cancer in Northern India.
    BJU Int, 95(1): 170-3. [Abstract] [Full-text]
28. The economic consequences of prostate and bladder cancer in the UK.
    BJU Int, 95(1): 59-63. [Abstract] [Full-text]
29. Prostate cancer: socio-economic, geographical and private-health insurance effects on care and survival.
    BJU Int, 95(1): 51-8. [Abstract] [Full-text]
30. Initial incision of lateral pelvic fascia and early ligation of vascular pedicles during radical prostatectomy: potential to reduce positive margin rates.
    BJU Int, 95(1): 40-5. [Abstract] [Full-text]
31. Radical prostatectomy: pathology findings in 1001 cases compared with other major series and over time.
    BJU Int, 95(1): 34-9. [Abstract] [Full-text]
32. Skeletal localization and neutralization of the SDF-1(CXCL12)/CXCR4 axis blocks prostate cancer metastasis and growth in osseous sites in vivo.
    J Bone Miner Res, 20(2): 318-29. [Abstract] [Full-text]
33. Risk of fracture after androgen deprivation for prostate cancer.
    N Engl J Med, 352(2): 154-64. [Abstract] [Full-text]
34. An unusual pathological finding of chronic lymphocitic leukemia and adenocarcinoma of the prostate after transurethral resection for complete urinary retention: case report.
    BMC Cancer, 4(1): 95. [Abstract] [Full-text]
35. Survey of genetically engineered mouse models for prostate cancer: analyzing the molecular basis of prostate cancer development, progression, and metastasis.
    J Cell Biochem, 94(2): 279-97. [Abstract] [Full-text]
36. The biology of a prostate cancer metastasis suppressor protein: Raf kinase inhibitor protein.
    J Cell Biochem, 94(2): 273-8. [Abstract] [Full-text]
37. MR-guided transgluteal biopsies with an open low-field system in patients with clinically suspected prostate cancer: technique and preliminary results.
    Eur Radiol, 15(1): 174-82. [Abstract] [Full-text]
38. Phase I trial on sms-D70 somatostatin analogue in advanced prostate and renal cell cancer.
    Ann N Y Acad Sci, 1028: 361-74. [Abstract] [Full-text]
39. Molecular biology and the staging of prostate cancer.
    Ann N Y Acad Sci, 1028: 294-312. [Abstract] [Full-text]
40. Signaling mechanisms that mediate invasion in prostate cancer cells.
    Ann N Y Acad Sci, 1028: 283-8. [Abstract] [Full-text]
41. Steroids as procarcinogenic agents.
    Ann N Y Acad Sci, 1028: 216-32. [Abstract] [Full-text]
42. Information priorities of Italian early-stage prostate cancer patients and of their health-care professionals.
    Patient Educ Couns, 56(2): 174-81. [Abstract] [Full-text]
43. Targeting tumor angiogenic vasculature using polymer-RGD conjugates.
    J Control Release, 102(1): 191-201. [Abstract] [Full-text]
44. The role of the stromal microenvironment in prostate cancer.
    Semin Cancer Biol, 15(2): 132-7. [Abstract] [Full-text]
45. Prostate carcinoma detection and increased prostate-specific antigen levels after 4 years in Dutch and Japanese males who had no evidence of disease at initial screening.
    Cancer, 103(2): 242-50. [Abstract] [Full-text]
46. Epigenetic changes in prostate cancer: implication for diagnosis and treatment.
    J Natl Cancer Inst, 97(2): 103-15. [Abstract] [Full-text]
47. Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT).
    J Natl Cancer Inst, 97(2): 94-102. [Abstract] [Full-text]
48. mtDNA mutations increase tumorigenicity in prostate cancer.
    Proc Natl Acad Sci U S A, 102(3): 719-24. [Abstract] [Full-text]
49. Tumor-targeting bacterial therapy with amino acid auxotrophs of GFP-expressing Salmonella typhimurium.
    Proc Natl Acad Sci U S A, 102(3): 755-60. [Abstract] [Full-text]
50. Depletion of CD25+ cells from human T-cell enriched fraction eliminates immunodominance during priming with dendritic cells genetically modified to express a secreted protein.
    Cancer Gene Ther, 12(2): 185-97. [Abstract] [Full-text]
51. Regional hyperthermia in conjunction with definitive radiotherapy against recurrent or locally advanced prostate cancer T3 pN0 M0.
    Strahlenther Onkol, 181(1): 35-41. [Abstract] [Full-text]
52. p42/p44 Mitogen-activated protein kinase signal transduction pathway regulates interleukin-6 expression in PC3 cells, a line of hormone-refractory prostate cancer cells.
    Ann N Y Acad Sci, 1030: 253-7. [Abstract] [Full-text]
53. p42/p44 Mitogen-activated protein kinase signal transduction pathway: a novel target for the treatment of hormone-resistant prostate cancer?
    Ann N Y Acad Sci, 1030: 243-52. [Abstract] [Full-text]
54. Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group.
    J Clin Oncol, 23(3): 455-60. [Abstract] [Full-text]
55. Comparison of trace metal concentrations in malign and benign human prostate.
    J Med Chem, 48(2): 630-4. [Abstract] [Full-text]
56. Men's values-based factors on prostate cancer risk genetic testing: a telephone survey.
    BMC Med Genet, 5: 28. [Abstract] [Full-text]
57. 17beta-Estradiol upregulates and activates WOX1/WWOXv1 and WOX2/WWOXv2 in vitro: potential role in cancerous progression of breast and prostate to a premetastatic state in vivo.
    Oncogene, 24(4): 714-23. [Abstract] [Full-text]
58. KAI1 promoter activity is dependent on p53, junB and AP2: evidence for a possible mechanism underlying loss of KAI1 expression in cancer cells.
    Oncogene, 24(4): 637-49. [Abstract] [Full-text]
59. Long-term survival rates of patients with prostate cancer in the prostate-specific antigen screening era: population-based estimates for the year 2000 by period analysis.
    J Clin Oncol, 23(3): 441-7. [Abstract] [Full-text]
60. Obesity and the risk of prostate cancer.
    Prostate, 62(4): 316-21. [Abstract] [Full-text]
61. Real-time whole-body imaging of an orthotopic metastatic prostate cancer model expressing red fluorescent protein.
    Prostate, 62(4): 374-9. [Abstract] [Full-text]
62. Cell proliferation and apoptosis in prostate tumors and adjacent non-malignant prostate tissue in patients at different time-points after castration treatment.
    Prostate, 62(4): 307-15. [Abstract] [Full-text]
63. Validity of three calliper-based transrectal ultrasound methods and digital rectal examination in the estimation of prostate volume and its changes with age: the Krimpen study.
    Prostate, 62(4): 353-63. [Abstract] [Full-text]
64. Transition of an androgen-dependent human prostate cancer cell line into an androgen-independent subline is associated with increased angiogenesis.
    Prostate, 62(4): 364-73. [Abstract] [Full-text]
65. Castration triggers growth of previously static androgen-independent lesions in the transgenic adenocarcinoma of the mouse prostate (TRAMP) model.
    Prostate, 62(4): 322-38. [Abstract] [Full-text]
66. Body mass index and the risk of male cancer mortality of various sites: 17-year follow-up of the Basel cohort study.
    Swiss Med Wkly, 135(1): 27-33. [Abstract] [Full-text]
67. Trends in reporting Gleason score 1991 to 2001: changes in the pathologist's practice.
    Eur Urol, 47(2): 196-201. [Abstract] [Full-text]
68. Feasibility and limitations of comorbidity measurement in patients undergoing radical prostatectomy.
    Eur Urol, 47(2): 190-5; discussion 195. [Abstract] [Full-text]
69. Validation of 2001 Partin tables in Turkey: a multicenter study.
    Eur Urol, 47(2): 185-9. [Abstract] [Full-text]
70. Influence of nerve-sparing (NS) procedure during radical prostatectomy (RP) on margin status and biochemical failure.
    Eur Urol, 47(2): 176-84. [Abstract] [Full-text]
71. Neuroendocrine differentiation in prostate cancer: implications for new treatment modalities.
    Eur Urol, 47(2): 147-55. [Abstract] [Full-text]
72. Small cell carcinoma of the prostate with hypercalcemia.
    Int J Urol, 12(1): 108-10. [Abstract] [Full-text]
73. Genistein induces cell growth inhibition in prostate cancer through the suppression of telomerase activity.
    Int J Urol, 12(1): 73-80. [Abstract] [Full-text]
74. Clinicopathological statistics on registered prostate cancer patients in Japan: 2000 report from the Japanese Urological Association.
    Int J Urol, 12(1): 46-61. [Abstract] [Full-text]
75. Determination of immunoreactive fraction of radiolabeled monoclonal antibodies: what is an appropriate method?
    Cancer Biother Radiopharm, 19(6): 706-15. [Abstract] [Full-text]
76. Behavioral associations between prostate and colon cancer screening.
    J Am Coll Surg, 200(2): 216-23. [Abstract] [Full-text]
77. Severe hypophosphatemic osteomalacia in hormone-refractory prostate cancer metastatic to the skeleton: natural history and pitfalls in management.
    Bone, 36(1): 1-5. [Abstract] [Full-text]
78. The role of Vitamin D3 metabolism in prostate cancer.
    J Steroid Biochem Mol Biol, 92(4): 317-25. [Abstract] [Full-text]
79. Interaction of nuclear receptor ligands with the Vitamin D signaling pathway in prostate cancer.
    J Steroid Biochem Mol Biol, 92(4): 307-15. [Abstract] [Full-text]
80. Role of estrogens in development of prostate cancer.
    J Steroid Biochem Mol Biol, 92(4): 297-305. [Abstract] [Full-text]
81. Endocrine treatment of prostate cancer.
    J Steroid Biochem Mol Biol, 92(4): 287-95. [Abstract] [Full-text]
82. Sex steroid hormone metabolism and prostate cancer.
    J Steroid Biochem Mol Biol, 92(4): 281-6. [Abstract] [Full-text]
83. Androgens, lipogenesis and prostate cancer.
    J Steroid Biochem Mol Biol, 92(4): 273-9. [Abstract] [Full-text]
84. Expression and function of androgen receptor coactivators in prostate cancer.
    J Steroid Biochem Mol Biol, 92(4): 265-71. [Abstract] [Full-text]
85. Alterations of androgen receptor in prostate cancer.
    J Steroid Biochem Mol Biol, 92(4): 255-64. [Abstract] [Full-text]
86. The epidemiology of sex steroid hormones and their signaling and metabolic pathways in the etiology of prostate cancer.
    J Steroid Biochem Mol Biol, 92(4): 237-53. [Abstract] [Full-text]
87. Hormonal, cellular, and molecular regulation of normal and neoplastic prostatic development.
    J Steroid Biochem Mol Biol, 92(4): 221-36. [Abstract] [Full-text]
88. Comparison of two in vivo models for prostate cancer: orthotopic and intratesticular inoculation of LNCaP or PC-3 cells.
    Int J Urol, 11(12): 1114-21. [Abstract] [Full-text]
89. Combined androgen blockade in the management of advanced prostate cancer: a sensible or ostensible approach.
    Int J Urol, 11(12): 1092-6. [Abstract] [Full-text]
90. Evaluating peer support for prostate cancer: the Prostate Cancer Peer Support Inventory.
    BJU Int, 95(1): 46-50. [Abstract] [Full-text]
91. CIL-102 interacts with microtubule polymerization and causes mitotic arrest following apoptosis in the human prostate cancer PC-3 cell line.
    J Biol Chem, 280(4): 2771-9. [Abstract] [Full-text]
92. High throughput screening of methylation status of genes in prostate cancer using an oligonucleotide methylation array.
    Carcinogenesis, 26(2): 471-9. [Abstract] [Full-text]
93. Dysregulated expression of S100A11 (calgizzarin) in prostate cancer and precursor lesions.
    Hum Pathol, 35(11): 1385-91. [Abstract] [Full-text]
94. Construction of tumor-specific toxins using ubiquitin fusion technique.
    Mol Ther, 11(2): 196-204. [Abstract] [Full-text]
95. Image-guided radiotherapy for prostate cancer by CT-linear accelerator combination: prostate movements and dosimetric considerations.
    Int J Radiat Oncol Biol Phys, 61(2): 561-9. [Abstract] [Full-text]
96. Synergistic cytotoxic effects of zoledronic acid and radiation in human prostate cancer and myeloma cell lines.
    Int J Radiat Oncol Biol Phys, 61(2): 535-42. [Abstract] [Full-text]
97. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995.
    Int J Radiat Oncol Biol Phys, 61(2): 415-9. [Abstract] [Full-text]
98. Failure definition-dependent differences in outcome following radiation for localized prostate cancer: can one size fit all?
    Int J Radiat Oncol Biol Phys, 61(2): 409-14. [Abstract] [Full-text]
99. A dose-escalation trial with the adaptive radiotherapy process as a delivery system in localized prostate cancer: analysis of chronic toxicity.
    Int J Radiat Oncol Biol Phys, 61(2): 400-8. [Abstract] [Full-text]
100. Radical retropubic prostatectomy after orthotopic liver transplantation.
     Urology, 65(1): 175. [Abstract] [Full-text]
101. Primary carcinoid tumor of prostate presenting with bone marrow metastases.
     Urology, 65(1): 174. [Abstract] [Full-text]
102. Reliability of remembered International Index of Erectile Function domain scores in men with localized prostate cancer.
     Urology, 65(1): 131-5. [Abstract] [Full-text]
103. Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment.
     Urology, 65(1): 126-30. [Abstract] [Full-text]
104. Cross-sectional survey of long-term quality of life after radical perineal prostatectomy.
     Urology, 65(1): 120-5. [Abstract] [Full-text]
105. Comparison of late rectal toxicity from conventional versus three-dimensional conformal radiotherapy for prostate cancer: analysis of clinical and dosimetric factors.
     Urology, 65(1): 114-9. [Abstract] [Full-text]
106. Predictors of fatigue after treatment for prostate cancer.
     Urology, 65(1): 101-8. [Abstract] [Full-text]
107. Influence of body mass index on biochemical outcome after permanent prostate brachytherapy.
     Urology, 65(1): 95-100. [Abstract] [Full-text]
108. Approach to management of clinically localized prostate cancer in patients with human immunodeficiency virus.
     Urology, 65(1): 91-4. [Abstract] [Full-text]
109. The dual 5-alpha-reductase inhibitor dutasteride induces atrophic changes and decreases relative cancer volume in human prostate.
     Urology, 65(1): 76-82. [Abstract] [Full-text]
110. Prevalence and characteristics of screen-detected prostate carcinomas at low prostate-specific antigen levels: aggressive or insignificant?
     BJU Int, 95(2): 231-7. [Abstract] [Full-text]
111. Confirmation of the HPCX prostate cancer predisposition locus in large Utah prostate cancer pedigrees.
     Hum Genet, 116(3): 179-85. [Abstract] [Full-text]
112. Mutation of the androgen receptor causes oncogenic transformation of the prostate.
     Proc Natl Acad Sci U S A, 102(4): 1151-6. [Abstract] [Full-text]
113. Three dimensional ultrasound and prostate cancer.
     World J Urol, 22(5): 339-45. [Abstract] [Full-text]
114. Differential expression of 37 selected genes in hormone-refractory prostate cancer using quantitative taqman real-time RT-PCR.
     Int J Cancer, 114(2): 174-81. [Abstract] [Full-text]
115. PET and prostate cancer.
     World J Urol, 22(5): 351-2. [Abstract] [Full-text]
116. Contrast specific imaging in the detection and localization of prostate cancer.
     World J Urol, 22(5): 346-50. [Abstract] [Full-text]
117. Doxorubicin increases the effectiveness of Apo2L/TRAIL for tumor growth inhibition of prostate cancer xenografts.
     BMC Cancer, 5(1): 2. [Abstract] [Full-text]
118. Randomized controlled trial to evaluate radiotherapy +/- endocrine therapy versus endocrine therapy alone for PSA failure after radical prostatectomy: Japan Clinical Oncology Group Study JCOG 0401.
     Jpn J Clin Oncol, 35(1): 34-6. [Abstract] [Full-text]
119. Outcome predictors for the increasing PSA state after definitive external-beam radiotherapy for prostate cancer.
     J Clin Oncol, 23(4): 826-31. [Abstract] [Full-text]
120. Individualized predictions of disease progression following radiation therapy for prostate cancer.
     J Clin Oncol, 23(4): 816-25. [Abstract] [Full-text]
121. Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer.
     J Clin Oncol, 23(4): 808-15. [Abstract] [Full-text]
122. Androgen suppression plus radiation versus radiation alone for patients with stage D1/pathologic node-positive adenocarcinoma of the prostate: updated results based on national prospective randomized trial Radiation Therapy Oncology Group 85-31.
     J Clin Oncol, 23(4): 800-7. [Abstract] [Full-text]
123. Expression of prostate specific membrane antigen in androgen-independent prostate cancer cell line PC-3.
     Arch Biochem Biophys, 435(1): 1-14. [Abstract] [Full-text]
124. A prospective evaluation of efficacy and compliance with a multistep treatment approach for erectile dysfunction in patients after non-nerve sparing radical prostatectomy.
     BJU Int, 95(3): 359-65. [Abstract] [Full-text]
125. Neither alpha-blocker therapy nor cystography is required before early catheter removal after radical prostatectomy.
     BJU Int, 95(3): 323-5. [Abstract] [Full-text]
126. Surgery for localized prostate cancer after renal transplantation.
     BJU Int, 95(3): 319-22. [Abstract] [Full-text]
127. Surgical margin status after radical retropubic prostatectomy.
     BJU Int, 95(3): 281-4. [Abstract] [Full-text]
128. Secretion of prostatic specific antigen, proliferative activity and androgen response in epithelial-stromal co-cultures from human prostate carcinoma.
     Int J Androl, 28(1): 39-46. [Abstract] [Full-text]

© 2004-2010 Prostate Cancer Research Today. All Rights Reserved.